This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stimson P. Schantz, MD; Gary Clayman, MD; Tamas Racz, MD; Elizabeth A. Grimm, PhD; Frank J. Liu, MD; Pierre Lavedan; Dorothy Taylor, MS; Candice Pellegrino; Howard Savage, PhD

Arch Otolaryngol Head Neck Surg. 1990;116(11):1302-1308.

Abstract
• Given the association of deficient natural immunity with the risk of metastatic disease, the ability to activate natural killer cell function may have a therapeutic significance. The effect of continuous infusion of interleukin 2 plus intramuscular interferon alfa on natural immune status was, therefore, analyzed in eight patients with head and neck cancer. Also evaluated was the effect of interleukin 2–interferon alfa therapy on lymphokine-activated killer cell activity as well as total lymphocyte count, percent of lymphocyte subsets, and levels of both circulating immune complexes and antibody classes. Both the percent and absolute number of natural killer cells (ie, CD56 CD3 lymphocytes) within peripheral blood as well as natural killer cell activity against K562 targets increased significantly with treatment. The remaining immune parameters were not significantly altered. The demonstrated capacity to modulate natural immune function supports the potential use of interleukin 2–containing regimens as a preventive measure against metastatic disease in patients with head and neck cancer.

(Arch Otolaryngol Head Neck Surg. 1990;116:1302-1308)

Author Affiliations
From the Departments of Head and Neck Surgery (Drs Schantz, Clayman, Racz, and Savage and Mr Lavedan and Mss Taylor and Pellegrino), Tumor Biology (Dr Grimm), and Laboratory Medicine (Dr Liu), The University of Texas M. D. Anderson Cancer Center, Houston.

Footnotes
Accepted for publication July 24, 1990.

Read before the American Society for Head and Neck Surgery, Palm Beach, Fla, May 1, 1990.

Reprint requests to Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, PO Box 69, 1515 Hol-combe Blvd, Houston, TX 77030 (Dr Schantz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck: A Phase 1 Study
To et al.
Arch Otolaryngol Head Neck Surg 2000;126:1225-1231.
ABSTRACT | FULL TEXT  

Interferon Gamma Enhances Lymphokine-Activated Killer Cell Adhesion but Not Lysis of Head and Neck Squamous Cell Carcinoma
Scher et al.
Arch Otolaryngol Head Neck Surg 1995;121:1271-1275.
ABSTRACT  

Induction of the Intercellular Adhesion Molecule (ICAM-1) on Squamous Cell Carcinoma by Interferon Gamma
Scher et al.
Arch Otolaryngol Head Neck Surg 1993;119:432-438.
ABSTRACT  

Natural Killer Cell Activity in Laryngeal Carcinoma
Gonzalez et al.
Arch Otolaryngol Head Neck Surg 1993;119:69-72.
ABSTRACT  

Effect of Wound Infections on Head and Neck Cancer
Ramadan and Wetmore
Arch Otolaryngol Head Neck Surg 1992;118:486-487.
ABSTRACT